Consolidated Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
Cash flows from operating activities:
Net loss	$ (66,369,311)	$ (56,582,857)
Loss from discontinued operations	30,267,990	22,016,524
Adjustments to reconcile net loss to net cash used in operating activities:
Common stock, stock options and warrants issued as payment for compensation, services rendered and interest expense	6,712,536	10,266,023
Depreciation and amortization	1,550,571	1,440,576
Amortization of preferred stock discount and issuance cost	1,609,495	2,440,241
Changes in fair value of derivative liability	(373,307)	(2,096,904)
Changes in acquisition-related contingent consideration	4,420,000	0
Write off of acquired in-process research and development	0	1,150,000
Loss on disposal of assets	13,653	0
Contributions paid with common stock	0	607,363
Bad debt expense (recovery)	511,755	(87,773)
Deferred income taxes	(175,533)	0
Prepaid expenses and other current assets	(178,011)	(350,227)
Accounts receivable	(554,884)	(443,132)
Inventory	(465,280)	(647,745)
Unearned revenues	178,008	948,452
Other assets	2,414,842	53,211
Accounts payable, accrued expenses and other current liabilities	1,677,551	(486,952)
Net cash used in operating activities - continuing operations	(18,759,925)	(21,773,200)
Net cash provided by operating activities - discontinued operations	4,907,407	845,206
Net cash used in operating activities	(13,852,518)	(20,927,994)
Cash flows from investing activities:
Cash received in acquisitions	0	320,863
Cash received in divestiture	12,280,000	0
Change in restricted cash used as collateral for notes payable	0	2,596
Acquisition of property and equipment	(531,315)	(574,857)
Net cash provided by (used in) investing activities - continuing operations	11,748,685	(251,398)
Net cash used in investing activities - discontinued operations	(5,660,305)	(1,803,182)
Net cash provided by (used in) investing activities	6,088,380	(2,054,580)
Cash flows from financing activities:
Net proceeds from exercise of options	0	7,100
Net proceeds from exercise of warrants	6,604,418	0
Net proceeds from issuance of capital stock	16,428,827	21,152,682
Repayment of mortgage loan	(196,585)	(149,542)
Proceeds from notes payable	666,501	149,766
Repayment of notes payable	(440,477)	(180,132)
Repayment of debt to related party	0	(3,000,000)
Repayment of preferred stock	(5,394,263)	(650,000)
Payment of dividend for preferred stock	(327,748)	0
Payment for warrant inducement	(228,676)	0
Net cash provided by financing activities - continuing operations	17,111,997	17,329,874
Net cash (used in) provided by financing activities - discontinued operations	(8,370,228)	2,739,496
Net cash provided by financing activities	8,741,769	20,069,370
Impact of changes of foreign exchange rates	14,389	46,245
Net increase (decrease) in cash and cash equivalents	992,020	(2,866,959)
Cash and cash equivalents at beginning of period	12,745,432	15,612,391
Cash and cash equivalents at end of period	13,737,452	12,745,432
Less cash and cash equivalents of discontinued operations at end of period	0	8,810,272
Cash and cash equivalents of continuing operations at end of period	13,737,452	3,935,160
Cash paid during the period for:
Interest	1,771,800	1,522,700
Taxes	2,100,000	1,119,500
Supplemental Schedule of non-cash investing activities:
Capitalized interest	182,000	384,300
Common stock, warrants and options received upon sale of Erye	1,117,901	0
Supplemental schedule of non-cash financing activities
Common stock, warrants and contingent consideration issued with the acquisition of Amorcyte	0	8,483,400
Common stock and warrants issued with the acquisition of PCT	0	17,200,000
Common stock issued pursuant to the redemption of Convertible Redeemable Series E 7% Preferred Stock	1,026,600	3,511,200
Common stock issued in payment of dividends for the Convertible Redeemable Series E 7% Preferred Stock	175,700	748,900
Dividend to related party reinvested as loan payable	$ 0	$ 11,726,100